Osimertinib for EGFR-mutant non-small cell lung cancer: place in therapy and future perspectives

Схожие документы

• Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer
  по: Lamberti, Giuseppe, et al.
  Опубликовано: (2019)
• First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC
  по: Ricciuti, Biagio, et al.
  Опубликовано: (2018)
• Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer
  по: Liam, Chong-Kin
  Опубликовано: (2017)
• The role of osimertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer
  по: Liam, Chong-Kin
  Опубликовано: (2019)
• A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients
  по: Cortellini, Alessio, et al.
  Опубликовано: (2020)